Skip to main content
Log in

Gemfibrozil and mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol—Pilot study

  • Lipids
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Plasma levels of lipoprotein-a [Lp(a)] >30 mg/dl represent an independent risk factor for cardiovascular diseases with both proatherosclerotic and prothrombotic activity. The results of dietary or pharmacological treatment are not encouraging and are often controversial. We have evaluated a combination of medical treatment with Gemfibrozil (600 mg bid) and a Mediterranean diet for 2 months in 15 patients with both hypercholesterolemia (>240 mg/dl) and high levels of Lp(a) (>30 mg/dl). Three patients dropped out within the first 2 weeks, complaining of epigastric pain and burning; the remainder (5 females and 7 males, mean age 70 years) completed the treatment without any side effects. The median values of Lp(a) decreased from 36.5 to 8.4 mg/dl (p<0.0002) and total cholesterol from 254.5 to 208.0 mg/dl (p<0.0001). The small number of patients does not permit any definitive conclusion on effectiveness to be drawn, but the results indicate further randomized studies might prove worthwhile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scanu AM, Fless GM. Lipoprotein (a)—Heterogeneity and biological relevance.J Clin Invest 1990;85:1709–1715.

    Google Scholar 

  2. Edelberg JM, Pizzo SV. Lipoprotein (a): The link between impaired fibrinolysis and atherosclerosis.Fibrinolysis 1991;5:135–143.

    Google Scholar 

  3. Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease.J Intern Med 1992;232:349–352.

    Google Scholar 

  4. Fidanza F. The Mediterranean Italian diet: Keys to contemporary thinking.Proc Nutr Soc 1991;50:519–526.

    Google Scholar 

  5. Hunninghake DB. Drug treatment of dyslipoproteinemia.Endocrinol Metab Clin North Am 1990;19:345–360.

    Google Scholar 

  6. Levine DM, Parker TS, Sloan BJ. Automated measurement of Lp(a) by immunoturbidimetric analysis.Int J Clin Lab Res 1992;22:173–178.

    Google Scholar 

  7. Boyer H, de Gennes JL, Truffert J, et al. Lp(a) levels in different types of dyslipidaemia in the French population.Atherosclerosis 1990;85:61–69.

    Google Scholar 

  8. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a).Atherosclerosis 1982;44:61–71.

    Google Scholar 

  9. Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.Circulation 1989;80:1313–1319.

    Google Scholar 

  10. Slunga L, Johnson O, Dahlen GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.Eur J Clin Pharmacol 1992;43:369–373.

    Google Scholar 

  11. Leren TP, Hjermann I, Foss OP, et al. Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects.Clin Invest 1992;70:711–718.

    Google Scholar 

  12. Gurakar AJ, Hoeg JM, Kostner GM, et al. Levels of lipoprotein (a) decline with neomycin and niacin treatment.Atherosclerosis 1985;57:293–301.

    Google Scholar 

  13. Beil FU, Terres W, Orgass M, Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia.Atherosclerosis 1991;90:95–97.

    Google Scholar 

  14. Gavish D, Breslow JL. Lipoprotein (a) reduction by N-acetylcysteine.Lancet 1991;337:203–204.

    Google Scholar 

  15. Scanu AM. N-acetylcysteine and immunoreactivity of lipoprotein(a) [letter].Lancet 1991;337:1159.

    Google Scholar 

  16. Frick MH, Elo O, Haapa K, Heinonen OP, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.N Engl J Med 1987;317:1237–1245.

    Google Scholar 

  17. Jones PH, Gotto AM, Pownall HJ, et al. Effect of gemfibrozil on plasma lipoprotein (a) levels in type IIa hyperlipoproteinemic subjects.Circulation 1991;84(Suppl):II483.

    Google Scholar 

  18. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone or in combination for the treatment of hypercholesterolemia.Am J Med 1993;94:13–20.

    Google Scholar 

  19. Bimmermann A, Boerschmann C, Schartzkopff W, Von Baeyer H, Schleicher J. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate.Curr Ther Res 1991;49:635–643.

    Google Scholar 

  20. Maggi FM, Biasi GM, Catapano AL. Reduction of Lp(a) plasma levels by bezafibrate.Atherosclerosis 1993;100:127–128.

    Google Scholar 

  21. Julius U, Hora C, Gross P, Fucker K, Bergmann S, Hanefeld M. Different effects of fibrates on lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types. of hyperlipoproteinemia.Fortschr Med 1992;110:669–672.

    Google Scholar 

  22. Thorogood M, Roe L, McPherson K, Mann J. Dietary intake and plasma lipid levels: Lessons from a study on the diet of health conscious group.Br Med J 1990;300:1297–1301.

    Google Scholar 

  23. Singh RB, Rastogi SS, Verma R, Laxami B, Singh R, Ghosh S. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year follow-up.Br Med J 1992;304:1015–1019.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simoni, G., Gianotti, A., Ardia, A. et al. Gemfibrozil and mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol—Pilot study. Cardiovasc Drug Ther 9, 347–350 (1995). https://doi.org/10.1007/BF00878680

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878680

Key Words

Navigation